Navigation Links
New Drug Application for Tolvaptan, Otsuka's Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
Date:12/21/2007

PRINCETON, N.J., Dec. 21 /PRNewswire/ -- Otsuka Pharmaceutical Development & Commercialization, Inc. announced today that the U.S. Food and Drug Administration has accepted a new drug application (NDA) for the company's investigational oral once-daily medication tolvaptan, a selective V2-vasopressin receptor antagonist, for two indications: treatment of adults with worsening heart failure and treatment of hyponatremia.(1) These indications are based on data from three phase 3 pivotal trials.(2)

OPDC was established in 2007 by Otsuka America, Inc. (OAI). OPDC is wholly owned by OAI, which is the holding company for Otsuka Pharmaceutical Co., Ltd. (OPC) interests in the U.S. OAI is wholly owned by OPC.

Tolvaptan is a novel, investigational small molecule designed to be an antagonist of the vasopressin V2 receptor, which plays a role in the kidney's regulation of fluid excretion. The majority of patients hospitalized for worsening heart failure have edema or excess body fluid, which is treated with diuretics to excrete the fluid. In contrast to diuretics, tolvaptan is designed to promote aquaresis, the excretion of electrolyte-free water. In clinical trials, the most common adverse reactions in patients with worsening heart failure (incidence greater than or equal to 5% in patients treated with tolvaptan and double the incidence of patients treated with placebo) were thirst, dry mouth and polyuria. In patients with hyponatremia, the most common adverse reactions in clinical trials (incidence greater than or equal to 5% in patients treated with tolvaptan and double the incidence of patients treated with placebo) were thirst, dry mouth, asthenia, constipation, pollakiuria and hyperglycemia. The most serious adverse events were cardiogenic shock (1.7% in patients receiving tolvaptan vs. 1.2% of patients receiving placebo), pulmonary embolism (1.3% in patients receiving tolvaptan vs. 0.8% for patients receiving placebo,) and gout (4.7% in patients rece
'/>"/>

SOURCE Otsuka Pharmaceutical Development & Commercialization,Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
3. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
4. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
5. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
6. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
7. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
8. Nitecs IND Application for Clinical Development With Lodotra Accepted by the FDA
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
11. Laser Energetics to Integrate BrightStar(TM) Alexandrite Lasers in Medical and Dental Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 OMICS ... Bioanalytical techniques during 18-20 August, 2014 at Double Tree ... review the recent developments in Analytical & Bioanalytical research ... globe. , Speaking on this occasion, Dr. Srinubabu Gedela, ... Analytica Acta conference is a remarkable one in bringing ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a firm ... today announced that it has acquired the Slim-Fast brand ... the business. Terms of the transaction were not disclosed. ... meal replacement business that markets ready-to-drink shakes, powders, bars ... America and in the United ...
(Date:7/10/2014)... fight against terrorism with the creation of a sensor ... use of light and special glass fibres. , Published ... , the researchers describe a novel optical fibre sensor ... 6.3 ppm (parts per million). It requires an analysis ... detection has involved looking for metals that encase them ...
(Date:7/10/2014)... lithium-ion batteries that power our laptops and electric vehicles ... single charge with the help of a sponge-like silicon ... replace the graphite traditionally used in one of the ... the energy storage capacity of graphite. A paper describing ... published today in Nature Communications . , "Silicon ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2Detecting trace amounts of explosives with light 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3
... -- bioTheranostics, a bioMerieux company that develops ... announced today study results published in the next issue ... to the clinical validity and the clinical utility of ... in the determination of the origin of a tumor. ...
... 2011 Peloton Therapeutics, Inc., an early-stage cancer drug ... an $18 million Series A financing.  Led by The ... O,Donnell, Jr., the Series A funds supplement a recently ... Research Institute of Texas (CPRIT). Peloton officials ...
... 2011 The Raymond and Ruth Perelman ... announces the launching of a first-of-its-kind interdisciplinary ... diseases. The Center will bring together, without institutional ... orphan diseases: establishing dedicated research support facilities, translating ...
Cached Biology Technology:New Study Reports CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility 2New Study Reports CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility 3Peloton Therapeutics Completes $18 Million Series A Financing 2Peloton Therapeutics Completes $18 Million Series A Financing 3Penn Receives $10 Million to Create Center for Orphan Disease Research and Therapy 2
(Date:7/11/2014)... have set a "mouse TRAP" to capture the early ... study published in the Journal of Clinical Investigation ... called TRAP to extract cellular and genetic information from ... at the Rockefeller Institute for Medical Research in 2008, ... machinery, or ribosomes, of the cell type of interest. ...
(Date:7/11/2014)... 2014, Shenzhen, China Researchers from Salk Institute for ... first time evaluated the safety and reliability of ... developed a new method, TALEN-HDAdV, which could significantly ... cell (hiPSC). This study published online in ... foundation for stem cell-based gene therapy. , The ...
(Date:7/11/2014)... Researchers from Ume University, Sweden, have explored two ... the reaction sequence leading to the formation of ... been published in the scientific journal Nature ... improving present day synthetic catalysts for water oxidation, ... devices for the direct storage of solar energy ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Molecular snapshots of oxygen formation in photosynthesis 2
... millipedes previously unknown in Australia has been discovered by ... of the widespread tropical family Pyrgodesmidae have been found among ... are not only widespread in Australia,s tropical and subtropical ... been published in the open access journal ZooKeys ...
... Trust and the Engineering and Physical Sciences Research Council ... initiative to find biomedical engineering solutions to challenging healthcare ... provide funding for a limited number of ground-breaking long-term ... are inadequate. Up to 10m over seven years is ...
... 29, 2012 The Crop Science Society of America (CSSA) ... during their Annual Meetings, Oct. 21-24, 2012 in Cincinnati, OH. ... professional achievements and meritorious service. Only 0.3 percent of the ... 2012 class of CSSA Fellows are: Marc C. ...
Cached Biology News:Millipede family added to Australian fauna 2£30 million boost for biomedical engineering research 2Crop Science Society of America presents 2012 class of fellows 2Crop Science Society of America presents 2012 class of fellows 3
... Agarose Spin Kit is an advanced system for isolating ... DNA can be used directly for any downstream application. ... is ready to use in 56 minutes Low ... for TAE and TBE gels No specialised equipment ...
... Spin Columns provide a rapid and simple method ... bp to 10 kb) from stained agarose gels ... excised from an agarose gel and loaded into ... the column are a series of membranes and ...
... Silica Bead Kit has been designed for recovery of ... Features Ultra fast protocol: DNA ... silica beads are easy to resuspend Bead uniformity ... pure DNA (suitable for PCR) DNA is eluted ...
... extraction of DNA fragments from 150 bp to > ... uses GelMelt solution to dissolve the gel slice, followed ... in a spin column format. After a wash step, ... spin column can bind up to 20 g DNA. ...
Biology Products: